Figure 5. TAF blocks the phosphorylation of AKT in
monocytes/MPs.
(A) The expression of AKT and mTOR in mock or TAF-treated STZ-injected,
HFHC diet-fed NASH mice liver tissues were analysed using western
blotting. The relative expression of phosphorylated proteins was
normalised to total protein expression. Data are representative of three
independent experiments. The graph in the right panel shows the
quantitative densitometry immunoblotting analysis results. (B)
Experimental scheme of isolated peripheral CD14+monocytes. Cells were pre-treated with TAF (1, 5 μM) for 6 h and
stimulated with 1 μg/mL LPS for 24 h. Dot plots of surface human
leukocyte antigen-DR isotype (HLA-DR) and PD-L1 levels in stimulated
monocytes treated with mock or TAF. Data are representative of five
independent experiments. (C) Frequency of
PD-L1+/HLA-DR+ cells in activated
CD14+ monocyte cells treated with mock or TAF. (D)
MFIs of PD-L1 and HLA-DR in activated CD14+ monocyte
cells after mock or TAF treatment. (E) Representative dot plots of AKT
and pAKT expression in mock or TAF-treated activated peripheral
CD14+ monocytes analysed using flow cytometry. MFI of
pAKT in mock- or TAF-treated activated peripheral
CD14+ monocytes, analysed using flow cytometry. (F)
Schematic representation of the TAF role in NASH liver. *p<0.05, **p <0.001, ***p<0.001.